“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
The Philippines pharmaceutical market is valued at USD 3.9 billion in 2018, reflecting a growth rate of 11.7%. Lupin’s subsidiary, MultiCare Pharmaceuticals Philippines Inc. (MultiCare), a premium branded generics company, generated total revenues of PHP 2,555 million, a decline of 20% compared to the previous year mainly due to the delay of TB tender deliveries to the Department of Health into the next fiscal. MultiCare has a strong presence in Diabetes, Women’s Health, Paediatrics, Respiratory, Central Nervous System and Oncology. MultiCare remains the 5th largest branded generic players in the Philippines.
